2020 Program 

saturday, february 29, 2020

7:00 AM - 4:00
Registration Open

7:00 - 8:00 AM
Special Interest Group Programming

8:00 - 9:00 AM
Small Group Breakfast Symposia (CASL Members)

• NUTRITION AND SARCOPENIA IN CIRRHOSIS IN HOSPITALIZED OR PRE‑TRANSPLANT PATIENTS

David Peretz, University of Manitoba
Natasha Chandok, University of British Columbia

• MANAGEMENT OF RENAL FAILURE IN CIRRHOSIS

Puneeta Tandon, University of Alberta
Phil Wong, McGill University

• Q&A NETWORKING SESSION ‑ HOW TO DEVELOP A SUCCESSFUL TRANSLATIONAL RESEARCH PROGRAM IN LIVER DISEASE

Chris Rose, Mark Swain
Craig Jenne, University of Calgary

9:00 - 10:20 AM
Concurrent Sessions

Public Health and Viral Hepatitis, Giada Sebastini & Mayur Brahmania

• Lifetime Trajectory of Chronic Liver Diseases and Changes in Global Epidemiology of Liver Disease, Jennifer Flemming, Queens University
• What Does the Future Hold for a HCV Vaccine? Naglaa Shoukry, University of Montréal
• Can We Afford to Screen and Treat HCV Infection in Canada? Latest Insight from a Canadian Policy Model - A Province-by-Province Analysis | William WL Wong | University of Waterloo
• Best Practice NAFLD, Screening, Triage, Management and Pediatric, Keyur Patel, UHN

Novel Imaging and Biomarkers in Liver Disease, Marc Deschenes & Saumya Jayakumar

• IgG4 Related Liver Disease, Ellie Barnes, Oxford University, UK
• Liver Imaging: Why CEUS? Stephanie Wilson, University of Calgary
• IL-16 as a New Marker for the Diagnosis of AIH/PBC Overlap Syndrome, Pascal Lapierre, CHUM
• Choosing Ammonia Wisely in End-Stage Liver Disease, Chris Rose, University of Montreal, CHUM

10:20 - 10:40 AM
Coffee Break

10:40 AM - 12:00 PM
SYMPOSIUM ‑ ISSUES RELEVANT TO PEDIATRIC AND ADULT LIVER DISEASE MANAGEMENT

Moderator: Orlee Guttman, University of British Columbia & Carla Coffin, CASL

• Transition of Care from Pediatric to Adult and Developmental Outcomes of Children with Chronic liver Disease (The Adult and the Pediatric Hepatologist Perspective), Marc Bilodeau, University of Montreal & Susan Gilmour, University of British Columbia
• The Changing Epidemiology of Hepatitis B and Update on HBV Vaccination (Including Novel Vaccine Formulations), Mandana Khalili, University of California, San Francisco
• A New Score Including Anthropometric Measurement for Weight Improved Prediction of Mortality of Adolescents on the Liver Transplantation Waiting List: US Nationwide Study, Abdel-Aziz Shaheen, University of Calgary
• Management of Sexual Dysfunction and Sex Hormone Abnormalities in Cirrhosis (Including Adolescence Development and Adults), Stephen Congly, University of Calgary

10:40 AM - 12:00 PM
CAHN Sessions - NURSE TRIAGE & SPECIAL TOPICS

Nursing Triage

1. Determining Fibrosis for Triage, Sarah De Coutere, NP-MN, Nova Scotia Health Authority
2. RN-based Referral Triage, Tracy Davyduke, RN, MS, Alberta Health Services

Special Topics

1. The Skinny on Fatty Liver Management: Brief Rationale for the Recommendations, Wendy Schaufert, RN, Alberta Health Services
2. Community Management of Decompensated Cirrhosis, Lindsay Myles, NP-PHC, Barrie & Community Family Health Team & Liver Care Canada
3. Hepatocellular Carcinoma: Screening to Liver Transplant and Everything in Between, Susan Allen, NP-MScN, Nova Scotia Health Authority

12:00 - 1:15 PM
Lunch Break / Poster Viewing / 5 E‑Poster Presentations

Moderator: Juan Gonzalez-Albrades

1:15 - 2:45 PM
ORAL ABSTRACT PRESENTATION

Scott Fung, UHN & Angela Crawley, The Ottawa Hospital Research Institute

1. Achieving Functional Cure of HBV and HBV / HDV Co-Infection with REP 2139: Completed Follow-Up in the REP 401 and REP 301-LTF Studies, Andrew Vaillant, REPLICOR
2. Micro-Elimination of Hepatitis C in A Population of Opioid Substitution Clients – Successful Task-Shifting of Testing and Treatment To A Community-Based Nurse/Pharmacist Dyad, Dennaye Fuchs, Saskatchewan Health Authority
3. Role of Pre and Post-Treatment Transient Elastography Measurements in Predicting Hepatocellular Carcinoma (HCC) Among Hepatitis C Patients Treated with Direct Acting Antivirals (DAA), Jacob Charette, University of Calgary
4. Addition of Peginterferon Alfa-2a Increases HBsAg Decline in HBeAg-Negative Chronic Hepatitis B Patients Treated with Long-Term Nucleos(t)ide Analogue Therapy: Results from a Multicenter Randomized Controlled Trial. (PAS Study), Mina Farag, Toronto Centre for Liver Disease
5. Integrating Community-Based Recruitment with Data Linkage to Inform and Enhance Scale-Up of HCV Treatment Among People who Inject Drugs in Canada: The VCCC Study Protocol, Stine Bordier Hoj, Université de Montréal
6. Increasing Hepatitis C Screening & New Diagnoses in 10 British Columbia Provincial Correctional Centres from 2010-2019, Sofia Bartlett, BC Centre for Disease control

2:45 - 4:05 PM
SYMPOSIUM ‑ STATE OF THE ART: ALCOHOL RELATED LIVER DISEASE

Kelly Burak, University of Calgary & Mang Ma

• Management of Acute / Chronic Liver Failure in Alcohol Related Liver Disease, Dean Karvellas, University of Alberta, Canada
• The Burden of Cirrhosis on the Canadian Health Care System: A Comparison Between Alcoholic and Nonalcoholic Cirrhosis Patients, Hassan Azhari, University of Calgary
• Trends in Burden and Management of Alcohol Related Liver Disease, Philippe Mathurin, Inserm, France
• Liver Transplantation for Alcoholic Hepatitis: A Debate, Anton Skaro, Western University vs Jeanne-Marie Giard, CHUM

4:00 - 5:00 PM
CAHN - NURSE‑LED MODELS OF CARE

Nurse-Led Models of Care

1. Overdose Prevention, Emmet O'Reilly, NP-PHC South Riverdale Community Health Centre
2. HCV Community Treatment in Northern Ontario, Shelly Archibald, RN, Sioux Lookout First Nations Health Authority
3. Medical Assistance in Dying (MAiD), Julie Campbell, MBA, NP-PHC, South West Local Health Integration Network, Ontario

4:05 - 4:20 PM
Coffee Break

4:20 - 5:40 PM
Concurrent Sessions

From Bench to Bedside: Inflammation and Liver Repair, Sonya MacParland, UHN & Andrew Mason, University of Alberta

• Repurposing Old Drugs for Autoimmune Liver Disease, Mark Swain, University of Calgary
• Fibrin and Fibrinogen in the Pathogenesis of NAFLD, Matthew Flick, University of North Carolina
• Impaired Hepatic Leukocyte Recruitment and Increased Thrombin Generation during Acute Bacterial Challenge in a Mouse Model of Non-Alcholic Fatty Liver Disease (NAFLD), Rachelle Davis, University of Calgary
• Autoimmune Hepatitis, Gideon Hirschfield, UHN

Clinical Workshop: Update on Diagnosis and Management of Portal Hypertension

Sam Lee, University of Calgary & Hin Hin Ko

• Novel Clinical Algorithms to Predict Decompensation in Cirrhosis, Juan Gonzalez Abraldes, University of Alberta
• Development in Portal Hypertensive Bleeding Management, a Therapeutic Gastroenterologist Perspective, Puja Kumar, University of Calgary
• Non-Invasive Surrogates of Portal Hypertension Predict Decompensation in Obese Patients with Compensated Advanced Chronic Liver Disease, Giada Sebastiani, McGill University
• Vascular Disorders of the Liver (i.e., Idiopathic Non-Cirrhotic Portal Hypertension), Julien Bissonnette, CHUM

4:20 - 5:40 PM
Concurrent Sessions

5:00 - 5:30 PM
CAHN - HCV ELIMINATION DEBATE

• Elimination Primer: Donna Zukowski, RN, CAHN President
• Be it resolved, that individuals with acute hepatitis C be treated immediately with no delay in order to meet Canadian targets for hepatitis C elimination.
• In favour of: Lisa Barrett, PhD, MD, Dalhousie University & Nova Scotia Health Authority
• Against: Hemant Shah, MD, MScCH, Toronto Centre for Liver Disease, University Health Network

5:30 - 7:00 PM
Special Interest Group Programming

CASL Special Topics - CaNAL

5:30 - 6:30 PM
Nurse Mixer Hosted by: CAHN

5:40 - 7:00 PM
Reception/ Poster Viewing

6:30 - 7:30 PM
CASL AGM